The prognostic value of inflammation-based scores in advanced hepatocellular carcinoma patients prior to treatment with sorafenib.
Fiche publication
Date publication
novembre 2017
Journal
Oncotarget
Auteurs
Membres identifiés du Cancéropôle Est :
Pr AYAV Ahmet, Pr BRONOWICKI Jean-Pierre, Pr PEIFFERT Didier
Tous les auteurs :
Conroy G, Salleron J, Belle A, Bensenane M, Nani A, Ayav A, Peiffert D, Lopez A, Baumann C, Barraud H, Bronowicki JP
Lien Pubmed
Résumé
The multikinase inhibitor sorafenib is the only currently approved drug for the indication of advanced hepatocellular carcinoma (HCC). It provides a limited gain in survival time but is frequently associated with adverse events. We currently lack simple prognostic factors in sorafenib-treated HCC patients. Various inflammation-based scores (IBSs) have been evaluated as predictors of tumor recurrence and survival in various malignancies (including HCC). The objective of the present study was to determine the prognostic value of IBSs for overall survival (OS) in advanced HCC patients prior to the initiation of sorafenib therapy.
Mots clés
HCC, inflammation-based scores, prognostic factor, sorafenib
Référence
Oncotarget. 2017 Nov 10;8(56):95853-95864